Actinium Pharmaceuticals Files 8-K on Officer/Director Changes
Ticker: ATNM · Form: 8-K · Filed: Nov 26, 2025 · CIK: 1388320
| Field | Detail |
|---|---|
| Company | Actinium Pharmaceuticals, Inc. (ATNM) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
Related Tickers: ACTM
TL;DR
Actinium Pharma (ACTM) filed an 8-K detailing leadership changes and shareholder votes.
AI Summary
Actinium Pharmaceuticals, Inc. filed an 8-K on November 26, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also covers the submission of matters to a vote of security holders. The company, incorporated in Delaware, is located at 100 Park Ave., New York, NY.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with votes by security holders, can signal internal shifts or strategic decisions that may carry inherent risks.
Key Players & Entities
- Actinium Pharmaceuticals, Inc. (company) — Registrant
- November 26, 2025 (date) — Date of earliest event reported
- 100 Park Ave., 23rd Floor, New York, NY 10017 (location) — Principal Executive Offices
- Delaware (location) — State of incorporation
FAQ
What specific items were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
Who are the departing directors or officers?
The filing states that it reports on the departure of directors or certain officers, but the names of these individuals are not specified in the provided text.
Who are the newly elected directors or appointed officers?
The filing mentions the election of directors and appointment of certain officers, but their identities are not detailed in the excerpt.
What are the details of the compensatory arrangements for certain officers?
The filing notes that compensatory arrangements of certain officers are covered, but the specifics of these arrangements are not included in the provided text.
What was the former name of Actinium Pharmaceuticals, Inc.?
The former name of Actinium Pharmaceuticals, Inc. was Cactus Ventures, Inc., with a date of name change on January 30, 2007.
Filing Stats: 807 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2025-11-26 17:00:53
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ATNM NYSE American Indi
Filing Documents
- ea026750301-8k_actinium.htm (8-K) — 34KB
- 0001213900-25-115586.txt ( ) — 197KB
- atnm-20251126.xsd (EX-101.SCH) — 3KB
- atnm-20251126_lab.xml (EX-101.LAB) — 33KB
- atnm-20251126_pre.xml (EX-101.PRE) — 22KB
- ea026750301-8k_actinium_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers;
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Class III Directors On November 26, 2025, Actinium Pharmaceuticals, Inc. (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting"). As previously reported in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 5, 2025 (the "Proxy Company's board of directors (the "Board") nominated each director for re-election at the Annual Meeting. At the Annual Meeting, each of Ajit S. Shetty and June S. Almenoff was elected as a Class III director of the Board to serve for a term expiring at the Company's 2028 annual meeting of stockholders.
07 Submission of Matters to a Vote of Security
Item 5.07 Submission of Matters to a Vote of Security Holders. A total of 15,494,573 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), were present in person or represented by proxy at the Annual Meeting. As of the close of business on October 15, 2025, the record date for the Annual Meeting, there were 31,195,891 shares of the Company's Common Stock issued and outstanding, with each share entitled to one vote. The matters described below were submitted to a vote of the holders of the Company's Common Stock at the Annual Meeting. Each proposal is described in detail in the Company's Proxy Statement. All proposals were approved by the Company's stockholders at the Annual Meeting. (1) To elect each of Dr. Ajit S. Shetty and Dr. June S. Almenoff as a Class III director to serve for a three-year term that expires at the 2028 Annual Meeting of Stockholders, or until his successor is elected and qualified or until his earlier resignation or removal: Director For Withhold Broker Non-Votes Ajit S. Shetty 5,032,369 1,234,852 9,354,877 June S. Almenoff 5,284,503 982,719 9,354,877 (2) To ratify the appointment of CBIZ as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025: For Against Abstain Broker Non-Votes 13,724,478 1,537,998 232,097 N/A (3) To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers: For Against Abstain Broker Non-Votes 4,481,875 1,541,460 243,885 9,354,877 (4) To approve three years as the frequency for future advisory votes to approve the compensation of the Company's named executive officers: 1 year 2 years 3 years Abstain Broker Non-Votes 4,645,270 210,365 1,284,061 127,523 9,354,877 For more information about the foregoing proposals, see the Proxy Statement, the relevant portions of which are incorporated herein by reference. The results report
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Actinium Pharmaceuticals, Inc. Date: November 26, 2025 /s/ Sandesh Seth Name: Sandesh Seth Title: Chairman and Chief Executive Officer